Shares of Hikma Pharmaceuticals PLC HIK rallied 2.61% to £19.64 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE 100 Index UKX rising 0. ...

Shares of Hikma Pharmaceuticals PLC HIK dropped 1.95% to £19.15 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE 100 Index UKX rising 0.38 ...

Hikma has completed its acquisition of Xellia Pharmaceuticals’ U.S. finished dosage form business and related assets following clearance under applicable U.S. antitrust laws. The acquisition ...

IBD is a chronic inflammation of the intestine characterised by severe stomach pain and diarrhoea affecting nearly 5 million people worldwide Riyadh – Hikma Pharmaceuticals KSA, announced the ...

Hikma Pharmaceuticals in the US joined government officials and non-profit leaders today at a naloxone awareness and training event organized and hosted by Rep. Earl L. "Buddy" Carter of Georgia.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Barclays cuts Prudential price target to 1,250 (1,380) pence - 'overweight' Barclays reinitiates Barratt Developments with 'overweight' - price target 641 pence Barclays raises HGCapital Trust to ...

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables ...

Also Read: Why Is Jazz Pharmaceuticals Stock Trading Lower ... and emphasized that other narcolepsy treatments are available. Hikma’s generic version of Xyrem only reached the market last ...